MIST Stock — Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals Inc (MIST)

Updated October 16, 2026.

MIST is a Stock. Total return is -95.4% over the past 7.4 years, 292.5 points behind SPY at 197.1%.

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines in the United States and Canada. Its lead product, CARDAMYST (etripamil) nasal spray, is a prescription medication for converting acute episodes of paroxysmal supraventricular tachycardia to normal heart rhythm in adults, and the company is also developing etripamil for atrial fibrillation with rapid ventricular rate. The company does not currently have an established distribution schedule, and information about its dividend or yield profile is not available.

MIST performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.4% over the past 7.4 years, 292.5 points behind SPY at 197.1%. Over the past year its total return — price change plus distributions reinvested — is -64.1%. Its deepest 1-year drawdown was 76.0%.

MIST key facts

Asset type

Stock

Asset class

Equity

Inception date

05/09/2019

Distribution frequency

None

Last close

$0.71 (as of 2026-10-16)

Market cap

$88,057,421

Average volume

974358.0

Beta

1.01

Payout ratio

0.0%

EPS

$-0.73

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MIST risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 76.0%.

Who may consider MIST — and who may not

It is a weaker fit for investors who need monthly cash flow (MIST does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MIST

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions